Junshi’s PD-1 blocker is already approved in China for metastatic melanoma. But it’s not stopping there—it plans to add other cancer types to the drug’s label, starting with throat cancer. The drug, ...
-
-
Recent Updates
- China’s Fibocom Pitches Cat M Module as a Buffer against Memory Supply Risk
- Instituto Sul Global and Shanghai Academy sign agreement to strengthen Brazil-China academic cooperation
- Chinese Import Charges Push Irish Shoppers to Rethink Online Buying
- Chinese Travelers Get Easier Pix Payments in Brazil through Weixin Pay
- AlphaPai Takes China AI Investment Research Platform to Global Markets
- China AI Stocks Slide as Nvidia Upheaval Revives US Chip Fears
- China Chip Links Deepen Scrutiny of Alice Huang and Nvidia Figure Jensen Huang
- Nvidia Scandal Deepens as China Links Raise Questions About Alice Huang
- Nvidia China Scandal Pulls Trump Administration Into Congressional Crossfire
- Wuhan to Shanghai on China’s fastest bullet train
Blogroll